Next Arc Research

Not logged in? You're viewing the Free tier. Join for free or log in to access your membership content.
Disclaimer: This content is for informational and educational purposes only and should not be construed as financial or investment advice. Always do your own research and consult a licensed financial advisor before making investment decisions.
Disclosure: The author holds a long position in TEM.
← Back to Free Index

TEM

Analysis as of: 2026-09-07
Tempus AI, Inc.
Tempus AI sells molecular diagnostics, clinical workflow software, and data-driven AI tools to physicians, health systems, researchers, and biopharma customers.
ai healthcare medical devices software
On Yahoo Finance ...
Jump to: Summary • Analysis • Opportunity • Risk • Trends • LE Structure • Third Party Analyst Consensus

Summary

Data rights can outrun software deflation
This is a mix-shift and control-point story, not just a test-volume story. The upside comes if embedded diagnostics, data rights, and verified oncology workflows mature faster than the market discounts, while regulation and reimbursement remain the main governor.

Analysis

Thesis
Tempus can compound faster than a normal diagnostics company because each test, workflow connection, and biopharma study enriches a permissioned data asset that generic AI cannot cheaply recreate; if Personalis closes and Tempus monetizes more verified actions instead of access alone, revenue mix and valuation quality can improve meaningfully by 2031.
Last Economy Alignment
Cheaper AI makes Tempus’ proprietary clinical data, regulated diagnostics, and embedded workflow rails more valuable, not less. It stops short of top-tier alignment because reimbursement, FDA, and proof gates still control how fast that advantage turns into cash.
Upgrade to Allocator to also access: Thesis Critique

Opportunity Outlook

Average Implied 5-Year Multiple
2.4x (from 5 most recent analyses)
Reasoning
This is a quality-of-growth story more than a pure test-volume story. I do not need the company to become a frontier model lab; I need it to turn a larger share of revenue into harder-to-replace oncology workflows, reimbursed diagnostics, and refreshed data products. If that happens, it can keep a premium valuation versus ordinary lab peers, though still below the most exuberant liquid-biopsy leaders.
Upgrade to Allocator to also access: Simplified Opportunity Explanation

Risk Assessment

Overall Risk Summary
The main risk is that Tempus remains strategically impressive but economically half-finished: reimbursement or FDA delays can slow assay monetization, Personalis can add integration and financing burden, and if buyers keep seeing the company mainly as a lab, the software and data layer may not earn the premium multiple needed for strong shareholder returns.
Upgrade to Allocator to also access: Tech Maturity Risk Score, Adoption Timing Risk Score, Moat Strength Risk Score, Capital Needs Risk Score, Regulatory Risk Score, Execution Risk Score, Concentration Risk Score, Unit Economics Risk Score, Valuation Risk Score, Macro Sensitivity Risk Score

Last Economy Structure

AI Industrial Score
0.70
They control a rare mix of cancer tests, provider connections, and permissioned patient data, so cheaper AI can make their information and workflow rails more valuable. The risk is that reimbursement rules, regulators, or bigger healthcare platforms stop that edge from turning into paid clinical actions.
Upgrade to Reader to also access: Score Decomposition, Confidence Level
Upgrade to Allocator to also access: Obsolescence Vectors, Pricing Fragility
Upgrade to Reader to also access: Constraint Benefit Score, Obsolescence Risk Score

Third Party Analyst Consensus

12-Month Price Target
$65.79
Upgrade to Reader to also access: Bull Case, Base Case, Bear Case